Pharma BD Deal Intelligence
Eli Lilly entered a multi-target, multi-modality strategic research collaboration and exclusive global license agreement with Cambridge, Massachusetts-based Stipple Bio to discover and commercialize cancer medicines directed at tumor-specific cell-surface epitopes identified on Stipple's Pointillist platform. Lilly receives exclusive worldwide rights to develop and commercialize resulting products. Stipple receives an undisclosed upfront payment plus an equity investment from Lilly, aggregate research, development and commercial milestone payments of up to $5.9 billion, and tiered royalties on product sales. The stated scientific rationale is to target epitopes present only on cancer cells to avoid the on-target/off-tumor toxicity that has limited prior cell-surface-directed oncology therapeutics.